| Cardiovascular Risk Management |
1 |
1 |
| Heart Failure (HF) |
0 |
0.95 |
| Hypertension |
0 |
0.9 |
| Heart |
0 |
0.59 |
| Pulmonary Arterial Hypertension |
0 |
0.49 |
| Cardiovascular disease |
0 |
0.99 |
| Cardiac MRI |
0 |
0.41 |
| Cardiovascular Imaging |
0 |
0.39 |
| Pulmonary Hypertension |
0 |
0.37 |
| Exercise |
0 |
0.29 |
| Chronic Kidney Disease |
0 |
0.25 |
| Anemia |
0 |
0.22 |
| Hemoglobin |
0 |
0.22 |
| Iron Deficiency Anemia |
0 |
0.2 |
| Guidelines for Hypertension |
0 |
0.16 |
| Clinical Guidelines |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Skeletal Myoblasts |
0 |
0.14 |
| Renal Failure |
0 |
0.13 |
| Renal Disease |
0 |
0.1 |
| COVID-19 |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Frailty |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Hemoglobinopathy |
0 |
0.07 |
| Intravenous |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| Match |
0 |
0.07 |
| Muscle |
0 |
0.07 |
| Myeloproliferative Disease |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Sarcoidosis |
0 |
0.07 |
| Skeletal |
0 |
0.07 |
| Tissue |
0 |
0.07 |
| Travel Medicine |
0 |
0.07 |
| UK Site Content |
0 |
0.07 |